Carboplatin with chemotherapy increases survival in triple-negative breast cancer: TMC study

Results showed a 77% survival rate in patients below 50 years who used carboplatin, an increase from the 66% without it ...
Governance Now

'Low-cost Carboplatin boosts survival in aggressive breast cancer'

Adding the inexpensive chemotherapy drug Carboplatin to standard treatment significantly improves survival in patients with ...

Mumbai News: Tata Memorial Centre Trial Shows Low-Cost Carboplatin Boosts Survival In Triple-Negative Breast Cancer

Mumbai: A landmark clinical trial led by Tata Memorial Centre (TMC), Mumbai, has found that adding the inexpensive ...